During the corresponding time, Crinetics Pharmaceuticals Inc recorded a revenue increase by 2336.28 % year on year, sequentially revenue grew by 134 %. While revenue at the Crinetics Pharmaceuticals Inc 's corporate clients
Crinetics Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company operates in the pharmaceutical sector with a focus on endocrinology. It develops and commercializes product candidates including PALSONIFY (paltusotine) and atumelnant. The company seeks patent protection and market exclusivities in jurisdictions such as the United States, Europe, China, Japan, and Brazil. Its intellectual property strategy is aligned with its commercial objectives across multiple pharmaceutical markets. Additionally, the company receives U.S. government funding through SBIR Grants awarded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, which may grant certain federal rights to related intellectual property.
News about Crinetics Pharmaceuticals Inc Contracts
Crinetics Pharmaceuticals, a clinical-stage biotechnology company focused on developing innovative therapeutics for rare endocrine diseases and endocrine-related tumors, has announced promising results from two separate studies evaluating the efficacy of their once-daily oral drug, paltusotine. In the Phase 3 PATHFNDR-2 study conducted in patients with acromegaly, paltusotine demonstrated significant effectiveness, achieving the primary and all secondary endpoints. Furthermore, the company had previously reported positive findings from an ongoing Phase 2 study investigating paltusotine for the treatment of carcinoid syndromeAcromegaly is a rare hormonal disorder caused by the excessive production of growth h...
Crinetics Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company operates in the pharmaceutical sector with a focus on endocrinology. It develops and commercializes product candidates including PALSONIFY (paltusotine) and atumelnant. The company seeks patent protection and market exclusivities in jurisdictions such as the United States, Europe, China, Japan, and Brazil. Its intellectual property strategy is aligned with its commercial objectives across multiple pharmaceutical markets. Additionally, the company receives U.S. government funding through SBIR Grants awarded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, which may grant certain federal rights to related intellectual property.
Sources:
Crinetics Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Crinetics Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Crinetics Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
136.73 %